Literature DB >> 7799506

Pattern of malignant bone tumour in northern areas of Pakistan.

M Ahmad1, A Ghani, A Mansoor, A H Khan.   

Abstract

A review of 280 primary malignant bone tumours diagnosed during 1984-1988 is presented. These constituted 3.14% of all malignant tumours. Male to female ratio was 2.3:1. Majority of these patients presented with rapidly growing mass, pain and deformity. Histologically, osteosarcoma was the most frequent (36.4%) primary malignant tumour. Male to female ratio was 3.31:1. More than 49% of these cases were in their second decade of life. In females the greatest frequency was in 10-15 years and in males 16-20 years age groups. Femur was the most frequent site. Other common malignant bone tumours included chondrosarcoma (22.1%), plasma cell myeloma (15.0%) and Ewings's sarcoma (8.6%). Miscellaneous cases of fibrosarcoma, chrodoma, adamentinoma and ameloblastoma were also seen. This study outlines the frequency, symptomatology and histological pattern of various malignant bone tumours in northern areas of Pakistan.

Entities:  

Mesh:

Year:  1994        PMID: 7799506

Source DB:  PubMed          Journal:  J Pak Med Assoc        ISSN: 0030-9982            Impact factor:   0.781


  3 in total

1.  Histopathological pattern of primary bone tumours and tumour-like lesions in Ile-Ife, Nigeria.

Authors:  Obafemi Joel Aina; Kayode Adebowale Adelusola; Ayodele Elkanah Orimolade; Akinola Akinmade
Journal:  Pan Afr Med J       Date:  2018-04-02

2.  X-ray and MRI Correlation of Bone Tumors Using Histopathology As Gold Standard.

Authors:  Hina Azad; Aliya Ahmed; Ibtesam Zafar; Muzammil Rasheed Bhutta; Muhammad Ali Rabbani; Himesh Raj Kc
Journal:  Cureus       Date:  2022-07-25

3.  Overview of extremity musculoskeletal neoplasms at the Ahmadu Bello University Teaching Hospital Zaria, Nigeria.

Authors:  Maitama Mohammed Inuwa; Lawal Yau Zakariyau; Dahiru I Ismail; Ejagwulu S Friday; Aniko A Ibrahim; Abdulmalik A Mohammed
Journal:  Ann Afr Med       Date:  2017 Jul-Sep
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.